Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome.
Jeanne L TheisGeorg VoglerMaria A MissinatoXing LiTanja NielsenXin-Xin I ZengAlmudena Martinez-FernandezStanley M WallsAnaïs KervadecJames N KezosKatja BirkerJared M EvansMegan M O'ByrneZachary C FogartyAndré TerzicPaul GrossfeldKaren OcorrTimothy J NelsonTimothy M OlsonAlexandre R ColasRolf BodmerPublished in: eLife (2020)
Congenital heart diseases (CHDs), including hypoplastic left heart syndrome (HLHS), are genetically complex and poorly understood. Here, a multidisciplinary platform was established to functionally evaluate novel CHD gene candidates, based on whole-genome and iPSC RNA sequencing of a HLHS family-trio. Filtering for rare variants and altered expression in proband iPSCs prioritized 10 candidates. siRNA/RNAi-mediated knockdown in healthy human iPSC-derived cardiomyocytes (hiPSC-CM) and in developing Drosophila and zebrafish hearts revealed that LDL receptor-related protein LRP2 is required for cardiomyocyte proliferation and differentiation. Consistent with hypoplastic heart defects, compared to patents the proband's iPSC-CMs exhibited reduced proliferation. Interestingly, rare, predicted-damaging LRP2 variants were enriched in a HLHS cohort; however, understanding their contribution to HLHS requires further investigation. Collectively, we have established a multi-species high-throughput platform to rapidly evaluate candidate genes and their interactions during heart development, which are crucial first steps toward deciphering oligogenic underpinnings of CHDs, including hypoplastic left hearts.
Keyphrases
- high throughput
- induced pluripotent stem cells
- single cell
- heart failure
- copy number
- atrial fibrillation
- endothelial cells
- signaling pathway
- poor prognosis
- case report
- low density lipoprotein
- genome wide
- binding protein
- quality improvement
- long non coding rna
- genetic diversity
- transcription factor
- pluripotent stem cells